Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study - Sidonio, R F, Jr; Thompson, A A; Peyvandi, F (Expert Rev Hematol, 2023)